AZNCF News and Press, AstraZeneca Plc From 01/14/21

Veeva is building the Industry Cloud for the global life sciences industry with solutions including a CRM suite, content and data management, and AI-powered data analytics. In Q3, Veeva reported a revenue growth rate of 34% y/y (acceleration) and a healthy gross margin of 72% (q/q imp...

IQVIA demonstrates a strong sequential growth pattern, in near recovery to pre-pandemic volumes. Management have reinstated the buyback program, with ~$1 billion in authorization, and look set on acquisition targeting across FY2021. We feel shares are worth ~$197 at this point, an...

Moderna's vaccine delay is hardly fault of its own. The bigger investment picture becomes visible when you ignore the small setbacks and concentrate on the larger factors - in this case, mRNA-1273's superior ease of storage and strong efficacy. Additions to the company's vaccine p...

2020 was a year of immense adversity and contrast, as stocks bounced back sharply from a pandemic-induced bear market. Biotechs play a pivotal role in managing down the pandemic as vaccine production ramps higher. January to provide further insights on multiple additional vaccine tria...

NVAX traded down in December, but there wasn't really any bad news from the company. NVAX did produce some good news with a US/Mexico trial of the company's COVID-19 vaccine getting underway. Competitors are making progress but a slower than expected vaccine rollout gives NVAX a b...

The world is awash with liquidity as interest rates remain at historic lows. Cheap liquidity is the fuel that will spark the next buyout bing in smaller cap biotech. A diversified ETF specializing in smaller cap biotechs is the perfect vehicle to capitalize on the trend as detaile...

AZN's COVID-19 vaccine received emergency use authorization in the U.K. AZN's Q3 revenue grew at 3% and EBITDA grew in the double-digit percentage range on cost-containment efforts. COVID-19 revenue could have a meaningful impact on AZN. It could be the shot in the arm the company...

FibroGen, Inc. is a commercial-stage global biopharmaceutical company developing and commercializing innovative therapeutics treating anemia, fibrotic diseases, and cancer. FibroGen's pipeline consists of two late-stage/commercialized therapeutics and one medical product all with seve...

Fears are rising that a new coronavirus variant could be spread more easily among the populace. It is unclear whether vaccines from PFE, MRNA, NVAX, or JNJ can protect against the new strain. If a vaccine emerges to treat the new coronavirus strain, then it could shake up the $39 ...

Novavax's COVID-19 vaccine has shown efficacy in clinical trials. Late-stage trials could commence within days. NVAX's vaccine can be stored at refrigerated temperatures. Mass doses could potentially be easier to distribute vis-a-vis PFE or MRNA. The stock trades at 2x projected 2...